As only 20% of hematologic tumors carry P53 mutations, yet the activity profiles favor hematologics over solid tumors, even ovarian cancers, where up to 80% of patients carry P53 mutations, the activities for both compounds appear to extend beyond their direct impact upon P53. The gene discussed is TP53; the disease is ovarian cancer.